Clinical Trial Update: COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect of contrasT [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluated whether combining N-acetylcysteine and bicarbonate could reduce contrast-induced nephropathy during PCI; the study has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)
• Sodium Bicarbonate (sodium bicarbonate)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Contrast Induced Nephropathy | Phase 2, Phase 3 | Status: COMPLETED